17 research outputs found

    Bio-inspired Mechanisms for Artificial Self-organised Systems

    Get PDF
    Research on self-organization tries to describe and explain forms, complex patterns and behaviours that arise from a collection of entities without an external organizer. As researchers in artificial systems, our aim is not to mimic self-organizing phenomena arising in Nature, but to understand and to control underlying mechanisms allowing desired emergence of forms, complex patterns and behaviours. In this paper we analyze three forms of self-organization: stigmergy, reinforcement mechanisms and cooperation. For each forms of self-organisation, we present a case study to show how we transposed it to some artificial systems and then analyse the strengths and weaknesses of such an approach

    Negotiation-Style Recommender Based on Computational Ecology in Open Negotiation Environments.

    Get PDF
    The system described herein represents the first example of a recommender system in digital ecosystems where agents negotiate services on behalf of small companies. The small companies compete not only with price or quality, but with a wider service-by-service composition by subcontracting with other companies. The final result of these offerings depends on negotiations at the scale of millions of small companies. This scale requires new platforms for supporting digital business ecosystems, as well as related services like open-id, trust management, monitors and recommenders. This is done in the Open Negotiation Environment (ONE), which is an open-source platform that allows agents, on behalf of small companies, to negotiate and use the ecosystem services, and enables the development of new agent technologies. The methods and tools of cyber engineering are necessary to build up Open Negotiation Environments that are stable, a basic condition for predictable business and reliable business environments. Aiming to build stable digital business ecosystems by means of improved collective intelligence, we introduce a model of negotiation style dynamics from the point of view of computational ecology. This model inspires an ecosystem monitor as well as a novel negotiation style recommender. The ecosystem monitor provides hints to the negotiation style recommender to achieve greater stability of an open negotiation environment in a digital business ecosystem. The greater stability provides the small companies with higher predictability, and therefore better business results. The negotiation style recommender is implemented with a simulated annealing algorithm at a constant temperature, and its impact is shown by applying it to a real case of an open negotiation environment populated by Italian companies.Fil: De La Rosa, Josep Lluis. Universidad de Girona; EspañaFil: Hormazábal, Nicolás. Universidad de Girona; EspañaFil: Aciar, Silvana Vanesa. Universidad Nacional de San Juan; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - San Juan; ArgentinaFil: Lopardo, Gabriel Alejandro. Universidad de Girona; EspañaFil: Trias, Albert. Universidad de Girona; EspañaFil: Montaner, Miquel. No especifíca

    Soberanía alimentaria, movimientos sociales y universidad: un intercambio de saberes

    Get PDF
    La problemática de la desigualdad social en la sociedad argentina cobra expresión en una multiplicidad de manifestaciones específicas, entre ellas, la de inseguridad alimentaria. La Universidad, tiene un papel indelegable, en la formación de profesionales con sólida competencia teórico-metodológica y fundamentos ético-políticos para desarrollar intervenciones profesionales - en el campo de la investigación, la docencia y en los espacios socio-ocupacionales. Como formadora de ciudadanos, debe generar ámbitos de debate en sus estudiantes y con los diferentes actores sociales, que tiendan a revertir las situaciones de desigualdad. Esta formación implica un proceso de reapropiación y construcción social del conocimiento y la orientación de los esfuerzos científicos hacia la solución de los problemas más acuciantes de la sociedad actual. Abordar la cuestión de la Soberanía Alimentaria desde la Universidad, implica, una propuesta que apunta a la construcción de un modelo pedagógico emancipa torio direccionado por valores de solidaridad, cooperación y la consideración ética de la importancia de la participación. La finalidad de brindar a los estudiantes de grado esta práctica educativa, desde el conocimiento de su realidad inmediata, fortalecida con elementos teóricos y prácticos, para producir una comprensión más fundamentada de los procesos sociales, la producción de un pensamiento crítico que supere la formación individual y que provea de herramientas sistemáticas es necesariamente un proceso colectivo.Eje temático 5: La articulación con la comunidad b - Programas y experiencias: Voluntariado, cooperación, proyectos de extensión y vinculación con el medioFacultad de Ciencias Agrarias y Forestale

    RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial

    Get PDF
    Background: passive immunotherapy is a therapeutic alternative for patients with COVID-19. Equine polyclonal antibodies (EpAbs) could represent a source of scalable neutralizing antibodies against SARS-CoV-2. Methods: we conducted a double-blind, randomized, placebo-controlled trial to assess efficacy and safety of EpAbs (INM005) in hospitalized adult patients with moderate and severe COVID-19 pneumonia in 19 hospitals of Argentina. Primary endpoint was improvement in at least two categories in WHO ordinal clinical scale at day 28 or hospital discharge (ClinicalTrials.gov number NCT04494984). Findings: between August 1st and October 26th, 2020, a total of 245 patients were enrolled. Enrolled patients were assigned to receive two blinded doses of INM005 (n = 118) or placebo (n = 123). Median age was 54 years old, 65 1% were male and 61% had moderate disease at baseline. Median time from symptoms onset to study treatment was 6 days (interquartile range 5 to 8). No statistically significant difference was noted between study groups on primary endpoint (risk difference [95% IC]: 5 28% [-3 95; 14 50]; p = 0 15). Rate of improvement in at least two categories was statistically significantly higher for INM005 at days 14 and 21 of follow-up. Time to improvement in two ordinal categories or hospital discharge was 14 2 (§ 0 7) days in the INM005 group and 16 3 (§ 0 7) days in the placebo group, hazard ratio 1 31 (95% CI 1 0 to 1 74). Subgroup analyses showed a beneficial effect of INM005 over severe patients and in those with negative baseline antibodies. Overall mortality was 6 9% the INM005 group and 11 4% in the placebo group (risk difference [95% IC]: 0 57 [0 24 to 1 37]). Adverse events of special interest were mild or moderate; no anaphylaxis was reported. Interpretation: Albeit not having reached the primary endpoint, we found clinical improvement of hospitalized patients with SARS-CoV-2 pneumonia, particularly those with severe disease.Fil: Lopardo, Gustavo. Municipalidad de Vicente Lopez (buenos Aires). Hospital Municipal Doctor Bernardo Houssay.; ArgentinaFil: Belloso, Waldo H.. Hospital Italiano; ArgentinaFil: Nannini, Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Colonna, Mariana. Inmunova; ArgentinaFil: Sanguineti, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Inmunova; ArgentinaFil: Zylberman, Vanesa. Inmunova; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Muñoz, Luciana. Inmunova; ArgentinaFil: Dobarro, Martín. Sanatorio Sagrado Corazón; ArgentinaFil: Lebersztein, Gabriel. Sanatorio Sagrado Corazón; ArgentinaFil: Farina, Javier. Gobierno de la Provincia de Buenos Aires. Hospital de Alta Complejidad Cuenca Alta Doctor Nestor Carlos Kirchner.; ArgentinaFil: Vidiella, Gabriela. Sanatorio Agote. Dr. Luis Agote; ArgentinaFil: Bertetti, Anselmo. Sanatorio Guemes Sociedad Anonima.; ArgentinaFil: Crudo, Favio. Universidad Nacional de San Antonio de Areco; ArgentinaFil: Alzogaray, Maria Fernanda. Instituto Medico Platense.; ArgentinaFil: Barcelona, Laura. Municipalidad de Vicente Lopez (buenos Aires). Hospital Municipal Doctor Bernardo Houssay.; ArgentinaFil: Teijeiro, Ricardo. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Doctor Ignacio Pirovano; ArgentinaFil: Lambert, Sandra. Provincia de Buenos Aires. Ministerio de Salud. Hospital Alta Complejidad en Red El Cruce Dr. Néstor Carlos Kirchner Samic; ArgentinaFil: Scublinsky, Darío. Clinica Zabala.; ArgentinaFil: Iacono, Marisa. Provincia del Neuquen. Hospital Provincial Neuquen "dr. E. Castro Rendon"; ArgentinaFil: Stanek, Vanina. Hospital Italiano; ArgentinaFil: Solari, Rubén. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas "Dr. Francisco Javier Muñiz"; ArgentinaFil: Cruz, Pablo. No especifíca;Fil: Casas, Marcelo Martín. Clinica Adventista Belgrano; ArgentinaFil: Abusamra, Lorena. Hospital Municipal Dr. Diego Thompson; ArgentinaFil: Luciardi, Héctor Lucas. Provincia de Tucuman. Ministerio de Salud. Sistema Provincial de Salud. Hosp. Centro de Salud "zenon Santillan"; ArgentinaFil: Cremona, Alberto. Hospital Italiano de La Plata; ArgentinaFil: Caruso, Diego. Hospital Español; ArgentinaFil: de Miguel, Bernardo. No especifíca;Fil: Perez Lloret, Santiago. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Universidad Abierta Interamericana. Secretaría de Investigación. Centro de Altos Estudios En Ciencias Humanas y de la Salud - Sede Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Millán, Susana. No especifíca;Fil: Kilstein, Yael. No especifíca;Fil: Pereiro, Ana. Fundación Mundo Sano; ArgentinaFil: Sued, Omar. Fundación Huésped; ArgentinaFil: Cahn, Pedro. Fundación Huésped; ArgentinaFil: Spatz, Linus. Inmunova; ArgentinaFil: Goldbaum, Fernando Alberto. Inmunova; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina. Universidad Nacional de San Martin. Centro de Rediseño E Ingenieria de Proteinas.; Argentin

    Argentine Intersociety Consensus on Urinary Infection 2018-2019

    Get PDF
    La Sociedad Argentina de Infectología y otras sociedades científicas han actualizado estas recomendaciones utilizando, además de información internacional, la de un estudio multicéntrico prospectivo sobre infecciones del tracto urinario del adulto realizado en Argentina durante 2016-2017. La bacteriuria asintomática debe ser tratada solo en embarazadas, a quienes también se las debe investigar sistemáticamente; los antibióticos de elección son nitrofurantoína, amoxicilina, amoxicilina-clavulánico, cefalexina y trimetoprimasulfametoxazol. Ante procedimientos que impliquen lesión con sangrado del tracto urinario se recomienda solicitar urocultivo para pesquisar bacteriuria asintomática, y, si resultara positivo, administrar antimicrobianos según sensibilidad desde inmediatamente antes hasta 24 horas luego de la intervención. En mujeres, la cistitis puede ser tratada con nitrofurantoina, cefalexina, o fosfomicina y no se recomienda usar trimetoprima-sulfametoxazol o fluoroquinolonas; en pielonefritis puede emplearse ciprofloxacina, cefixima o cefalexina si el tratamiento es ambulatorio o ceftriaxona, cefazolina o amikacina si es hospitalario. En los hombres, las infecciones del tracto urinario se consideran siempre complicadas. Se recomienda tratamiento con nitrofurantoina o cefalexina por 7 días, o bien monodosis con fosfomicina. Para la pielonefritis en hombres se sugiere ciprofloxacina, ceftriaxona o cefixima si el tratamiento es ambulatorio y ceftriaxona o amikacina si es hospitalario. Se sugiere tratar las prostatitis bacterianas agudas con ceftriaxona o gentamicina. En cuanto a las prostatitis bacterianas crónicas, si bien su tratamiento de elección hasta hace poco fueron las fluoroquinolonas, la creciente resistencia y ciertasdudas sobre la seguridad de estas drogas obligan a considerar el uso de alternativas como fosfomicina.The Argentine Society of Infectious Diseases and other scientific societies have updated these recommendations based on data on urinary tract infections in adults obtained from a prospective multicenter study conducted in Argentina during 2016-2017. Asymptomatic bacteriuria should be treated only in pregnant women, who should also be systematically investigated; the antibiotics of choice are nitrofurantoin, amoxicillin, clavulanic/amoxicillin, cephalexin and trimethoprim-sulfamethoxazole. In procedures involving injury to the urinary tract with bleeding, it is recommended to request urine culture and, in the presence of bacteriuria, antimicrobial treatment according to sensitivity should be prescribed from immediately before up to 24 hours after the intervention. In women, cystitis can be treated with nitrofurantoin, cephalexin or fosfomycin, while trimethoprim-sulfamethoxazole and fluoroquinolones are not recommended; pyelonephritis can be treated with ciprofloxacin, cefixime or cephalexin in ambulatory women or ceftriaxone, cefazolin or amikacin in those who are hospitalized. In men, urinary tract infections are always considered complicated; nitrofurantoin or cephalexin are recommended for 7 days, alternatively fosfomycin should be given in a single dose. In men, ciprofloxacin, ceftriaxone or cefixime are suggested for pyelonephritis on ambulatory treatment whereas ceftriaxone or amikacin are recommended for hospitalized patients. Acute bacterial prostatitis can be treated with ceftriaxone or gentamicin. Fluoroquinolones were the choice treatment for chronic bacterial prostatitis until recently; they are no longer recommended due to the increasing resistance and recent concerns regarding the safety of these drugs; alternative antibiotics such as fosfomycin are to be considered.Fil: Nemirovsky, Corina. Sociedad Argentina de Infectologia; ArgentinaFil: Lopez Furst, María José. Sociedad Argentina de Infectologia; ArgentinaFil: Pryluka, Daniel. Sociedad Argentina de Infectologia; ArgentinaFil: de Vedia, Lautaro. Sociedad Argentina de Infectologia; ArgentinaFil: Scapellato, Pablo. Sociedad Argentina de Infectologia; ArgentinaFil: Colque, Angel. Sociedad Argentina de Infectologia; ArgentinaFil: Barcelona, Laura. Sociedad Argentina de Infectologia; ArgentinaFil: Desse, Javier. Sociedad Argentina de Infectologia; ArgentinaFil: Caradont, Matías. Sociedad Argentina de Urología; ArgentinaFil: Varcasia, Daniel. Sociedad Argentina de Urología; ArgentinaFil: Ipohorski,Gabriel. Federación Argentina de Urología; ArgentinaFil: Votta, Roberto. Federación Argentina de Sociedades de Ginecología y Obstetricia; ArgentinaFil: Zylberman, Marcelo. Sociedad Argentina de Medicina; ArgentinaFil: Romani, Adriana de Fátima. Sociedad Argentina de Medicina; ArgentinaFil: Valdez, Pascual. Sociedad Argentina de Medicina; ArgentinaFil: Penini, Magdalena. Sociedad Argentina de Bacteriología, Micología y Parasitología Clínica; ArgentinaFil: De Paulis, Adriana. Sociedad Argentina de Bacteriología, Micología y Parasitología Clínica; ArgentinaFil: Lucero, Celeste. Dirección Nacional de Instituto de Investigación.Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"; ArgentinaFil: Sandor, Andres. Sociedad Argentina de Infectología; ArgentinaFil: Contreras, Rosita. Sociedad Argentina de Infectología; ArgentinaFil: Nannini, Esteban. Sociedad Argentina de Infectología; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; ArgentinaFil: Gañete, Marcelo. Sociedad Argentina de Infectología; ArgentinaFil: Ralli, Hector. Sociedad Argentina de Infectología; ArgentinaFil: Lopardo, Gustavo. Sociedad Argentina de Infectología; ArgentinaFil: Mykietiuk, Analia. Sociedad Argentina de Infectología; ArgentinaFil: Aronson, Sandra. Sociedad Argentina de Infectología; ArgentinaFil: Fernández Laus, Adriana. Sociedad Argentina de Infectología; ArgentinaFil: Fernández Garces, Alejandro. Sociedad Argentina de Infectología; ArgentinaFil: Rodríguez, Claudia. Sociedad Argentina de Infectología; ArgentinaFil: Chattas, Ana. Sociedad Argentina de Infectología; ArgentinaFil: Farina, Javier. Sociedad Argentina de Infectología; ArgentinaFil: Clara, Liliana. Sociedad Argentina de Infectología; ArgentinaFil: Nuccetelli, Yanina. Sociedad Argentina de Infectología; ArgentinaFil: Amalfa, Flavia. Sociedad Argentina de Infectología; Argentin

    Embodied Autonomy in Digital Ecosystems: From Bio-Inspired Agents to Cognitive Systems

    No full text
    This paper proposes to promote autonomy in digital ecosystems so that it provides agents with information to improve the behavior of the digital ecosystem in terms of stability. This work proposes that, in digital ecosystems, autonomous agents can provide fundamental services and information. The final goal is to run the ecosystem, generate novel conditions and let agents exploit them. A set of evaluation measures must be defined as well. We want to provide an outline of some global indicators, such as heterogeneity and diversity, and establish relationships between agent behavior and these global indicators to fully understand interactions between agents, and to understand the dependence and autonomy relations that emerge between the interacting agents. Individual variations, interaction dependencies, and environmental factors are determinants of autonomy that would be considered. The paper concludes with a discussion of situations when autonomy is a mileston

    Embodied Autonomy in Digital Ecosystems: From Bio-Inspired Agents to Cognitive Systems

    No full text
    This paper proposes to promote autonomy in digital ecosystems so that it provides agents with information to improve the behavior of the digital ecosystem in terms of stability. This work proposes that, in digital ecosystems, autonomous agents can provide fundamental services and information. The final goal is to run the ecosystem, generate novel conditions and let agents exploit them. A set of evaluation measures must be defined as well. We want to provide an outline of some global indicators, such as heterogeneity and diversity, and establish relationships between agent behavior and these global indicators to fully understand interactions between agents, and to understand the dependence and autonomy relations that emerge between the interacting agents. Individual variations, interaction dependencies, and environmental factors are determinants of autonomy that would be considered. The paper concludes with a discussion of situations when autonomy is a mileston
    corecore